PubRank

Samuel Waxman

Author PubWeight™ 70.71‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 2008 4.35
2 Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008 4.03
3 Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology 2007 3.85
4 Mechanisms of action of arsenic trioxide. Cancer Res 2002 3.68
5 Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. J Clin Invest 2009 2.79
6 All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A 2004 2.67
7 The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. Blood 2007 2.58
8 Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology 2013 2.42
9 Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A 2009 2.34
10 A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 2006 2.32
11 Differentiation therapy of acute myeloid leukemia: past, present and future. Curr Opin Hematol 2009 1.95
12 MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology 2011 1.77
13 Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci U S A 2005 1.67
14 Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models. Cancer Prev Res (Phila) 2011 1.61
15 JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells. Blood 2003 1.38
16 The histone deacetylase 9 gene encodes multiple protein isoforms. J Biol Chem 2003 1.32
17 Melanoma differentiation associated gene-7, mda-7/interleukin-24, induces apoptosis in prostate cancer cells by promoting mitochondrial dysfunction and inducing reactive oxygen species. Cancer Res 2003 1.25
18 Fibrolamellar carcinoma: a review with focus on genetics and comparison to other malignant primary liver tumors. Semin Liver Dis 2011 1.17
19 Tamoxifen stimulates the growth of cyclin D1-overexpressing breast cancer cells by promoting the activation of signal transducer and activator of transcription 3. Cancer Res 2008 1.13
20 Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol Cancer Ther 2002 1.11
21 Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide. Cancer Res 2006 1.10
22 Induction of reactive oxygen species renders mutant and wild-type K-ras pancreatic carcinoma cells susceptible to Ad.mda-7-induced apoptosis. Oncogene 2005 1.09
23 DNA methylation-independent loss of RARA gene expression in acute myeloid leukemia. Blood 2007 1.01
24 Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells. Cancer Res 2003 0.99
25 Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk. Blood 2002 0.98
26 Bortezomib enhances the efficacy of fulvestrant by amplifying the aggregation of the estrogen receptor, which leads to a proapoptotic unfolded protein response. Clin Cancer Res 2011 0.97
27 Buthionine sulfoximine enhancement of arsenic trioxide-induced apoptosis in leukemia and lymphoma cells is mediated via activation of c-Jun NH2-terminal kinase and up-regulation of death receptors. Cancer Res 2006 0.97
28 LIM protein Ajuba functions as a nuclear receptor corepressor and negatively regulates retinoic acid signaling. Proc Natl Acad Sci U S A 2010 0.96
29 Interference with Sin3 function induces epigenetic reprogramming and differentiation in breast cancer cells. Proc Natl Acad Sci U S A 2010 0.94
30 Boswellic acid acetate induces apoptosis through caspase-mediated pathways in myeloid leukemia cells. Mol Cancer Ther 2005 0.94
31 Retinoic acid receptor alpha2 is a growth suppressor epigenetically silenced in MCF-7 human breast cancer cells. Cell Growth Differ 2002 0.93
32 Dual effects of glutathione-S-transferase pi on As2O3 action in prostate cancer cells: enhancement of growth inhibition and inhibition of apoptosis. Oncogene 2004 0.92
33 Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model. J Natl Cancer Inst 2006 0.90
34 Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide. Oncologist 2002 0.89
35 Glutathione-S-transferase pi inhibits As2O3-induced apoptosis in lymphoma cells: involvement of hydrogen peroxide catabolism. Blood 2004 0.88
36 Differentiation induction as a treatment for hematologic malignancies. Oncogene 2002 0.87
37 Ethacrynic acid and a derivative enhance apoptosis in arsenic trioxide-treated myeloid leukemia and lymphoma cells: the role of glutathione S-transferase p1-1. Clin Cancer Res 2012 0.86
38 Combination of cytotoxic-differentiation therapy with 5-fluorouracil and phenylbutyrate in patients with advanced colorectal cancer. Anticancer Res 2007 0.85
39 Targeted removal of PML-RARalpha protein is required prior to inhibition of histone deacetylase for overcoming all-trans retinoic acid differentiation resistance in acute promyelocytic leukemia. Blood 2002 0.85
40 Arsenic trioxide in multiple myeloma: rationale and future directions. Cancer J 2002 0.84
41 CD44 ligation with A3D8 antibody induces apoptosis in acute myeloid leukemia cells through binding to CD44s and clustering lipid rafts. Cancer Biol Ther 2012 0.83
42 Clinical translation of epigenetics in cancer: eN-CORe--a report on the second workshop. Mol Cancer Ther 2005 0.82
43 Progress in differentiation induction as a treatment for acute promyelocytic leukemia and beyond. Cancer Res 2002 0.81
44 Variant-type PML-RAR(alpha) fusion transcript in acute promyelocytic leukemia: use of a cryptic coding sequence from intron 2 of the RAR(alpha) gene and identification of a new clinical subtype resistant to retinoic acid therapy. Proc Natl Acad Sci U S A 2002 0.80
45 Targeting the ubiquitin-proteasome pathway in cancer therapy. Anticancer Agents Med Chem 2007 0.80
46 Derepression in the desert: the third workshop on clinical translation of epigenetics in cancer therapeutics. Cancer Res 2008 0.79
47 The cleavage product deltaPML-RARalpha contributes to all-trans retinoic acid-mediated differentiation in acute promyelocytic leukemia cells. Oncogene 2003 0.79
48 Molecular target-based treatment of human cancer: summary of the 10th international conference on differentiation therapy. Cancer Res 2005 0.79
49 State of the translational science: summary of Baltimore workshop on gene re-expression as a therapeutic target in cancer January 2003. Clin Cancer Res 2004 0.78
50 Benzodithiophenes potentiate differentiation of acute promyelocytic leukemia cells by lowering the threshold for ligand-mediated corepressor/coactivator exchange with retinoic acid receptor alpha and enhancing changes in all-trans-retinoic acid-regulated gene expression. Cancer Res 2005 0.78
51 Benzodithiophenes induce differentiation and apoptosis in human leukemia cells. Cancer Res 2005 0.75
52 A retinoid/butyric acid prodrug overcomes retinoic acid resistance in leukemias by induction of apoptosis. Mol Cancer Res 2003 0.75
53 Meeting report: the 11th International Conference on Differentiation Therapy and Innovative Therapeutics in Oncology. Cancer Res 2007 0.75